Estrogens (Estrogen)

27300 relevant articles (1041 outcomes, 3527 trials/studies) found for this Drug

Description: Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.

Also Known As:

Estrogen; Estrogenic Agents; Estrogenic Compounds; Agents, Estrogenic; Compounds, Estrogenic

Subscribe to New Research on Estrogens

Relationship Network

Drug Context: Research Results

Chemical Actions and Uses

Pharmacologic Actions: 49

Physiological Effects of Drugs: 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Hormones: 43419

Estrogens: 27300

Non-Steroidal Estrogens: 9

Related Diseases

1.	Neoplasms (Cancer) 01/01/1988 - "The features that most influenced prognosis within the categories defined by site of first relapse were disease-free interval (less than 24 months v greater than or equal to 24 months), and estrogen receptor content in the primary tumor" 10/01/1987 - "Because of its very high affinity and unusual dissociation kinetics, [3H]11 beta-CME2 should be a very useful ligand for studies of estrogen receptor dynamics and in the assay of estrogen receptor concentrations in tumors and tissues." 01/01/2004 - "In particular, we found a marked decrease in the number of apoptotic cells and debris after estrogen + irradiation, as compared to irradiation alone, only in younger patients and TNM 1+2 tumors" 01/01/1980 - "Jensen (1978) and Knight et al (1977) observed that patients with no or very low estrogen-receptor content in their tumors have a shorter disease-free interval" 10/01/1994 - "PATIENTS AND METHODS: One hundred sixty-seven good-risk patients with an estrogen receptor (ER+) positive recurrence or, in case of unknown receptor status, a disease-free interval (DFI) of greater than 12 months and < or = three recurrent tumor nodules each < or = 3 cm in diameter were entered onto the study" Get all the results and reference details, order at left...
2.	Breast Neoplasms (Breast Cancer) 03/01/2000 - "The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo" 05/01/1992 - "The results of this study with human breast cancer cells suggest that 5a may be highly effective in the treatment of estrogen-dependent breast cancer and/or in the prophylactic treatment of women with a high risk of breast cancer development." 12/01/2007 - "MDA-MB-231 is an estrogen receptor negative highly invasive human breast cancer cell line and has been used as a relevant model system to evaluate drugs with chemopreventive potential against highly invasive breast cancer phenotypes" 06/01/1983 - "Breast tumors are known to be heterogeneous with respect to estrogen receptor (ER) status, and the low complete remission rate may be secondary to this biochemical heterogeneity" 01/01/1983 - "Estrogen receptor (ER) has been well documented as an important predictor of long disease-free intervals and survival for patients with primary breast cancer (1)" Get all the results and reference details, order at left...
3.	Osteoporosis 01/01/2008 - "Because of the striking resemblance of skeletal responses in humans and rats in the state of estrogen deficiency, the ovx rat is considered to be a gold standard model for evaluating drugs for prevention and reversal of osteoporosis" 09/01/2001 - "Estrogen, especially when begun early in menopause, has been shown to be beneficial in the prevention and treatment of osteoporosis" 01/01/2000 - "Lower-dose combinations of continuous combined estrogen-progestin regimens are effective in increasing and maintaining BMD and provide a good endometrial safety profile for the long-term prevention of osteoporosis in postmenopausal women." 03/01/1988 - "Progestin supplementation also may augment the beneficial effects of estrogens in providing protection against osteoporosis, although this effect is not yet well established" 03/01/1988 - "On balance, estrogen therapy appears to be beneficial for menopausal women, as it probably reduces the risks of CAD and osteoporosis, two of the major causes of mortality and morbidity" Get all the results and reference details, order at left...
4.	Cardiovascular Diseases (Cardiovascular Disease) 10/01/2003 - "At the cellular level, estrogens have many effects on cardiovascular cells capable of being interpreted as beneficial in terms of cardiovascular disease" 11/01/2001 - "It is widely accepted that in women, estrogens provide protection against the development of cardiovascular disease" 09/01/2007 - "Previous studies demonstrated the protective effects of estrogen administration in models of cardiovascular disease" 12/25/2003 - "Clinical epidemiologic data and animal experimental studies regard estrogen as being protective against the development of cardiovascular diseases" 01/01/2008 - "Estrogen may have protective effects in the cardiovascular system, as evidenced by the decreased incidence of cardiovascular disease (CVD) in premenopausal compared with postmenopausal women" Get all the results and reference details, order at left...
5.	Carcinoma (Carcinomatosis) 02/15/1988 - "These characteristics are reflected in the marked efficacy with which it affects growth of estrogen-dependent 7,12-dimethylbenz(a)antracene-induced mammary carcinomas in intact female Sprague-Dawley rats" 07/01/1975 - "In darkness the percentage of the take of the carcinoma proved to be less, and also the growth of the RMC-1 was delayed; there was also a marked increase in the efficacy of estrogen-therapy of mammary carcinoma" 12/15/1980 - "This study corroborates previous reports which suggested the efficacy of estrogen receptor (ER) analysis in predicting responses of patients with metastatic mammary carcinoma to hormonal therapeutic manipulation" 06/01/1980 - "Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival." 01/01/1991 - "The promising results obtained in a pilot study of parenteral estrogen therapy in patients with prostatic carcinoma await confirmation in a randomised study, but where treatment with estrogen is considered for these patients, it may be that parenteral administration would be preferable." Get all the results and reference details, order at left...
1218 Diseases and 27300 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Tamoxifen
2.	Estrogens (Estrogen)
3.	Hormones
4.	Progesterone Receptors (Progesterone Receptor)
5.	Progesterone
6.	Estrogen Receptor Modulators (Antiestrogen)
7.	Progestins (Progestagens)
8.	Estradiol (Estrace)
9.	Aromatase Inhibitors
10.	Gonadotropin-Releasing Hormone (GnRH)
2676 Drugs and Important Bio-Agents and 16911 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Estrogen Replacement Therapy
3.	Drug Therapy (Chemotherapy)
4.	Ovariectomy (Oophorectomy)
5.	Orchiectomy (Orchidectomy)
143 Therapies and Procedures and 1997 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>